Professor Carl Clarke

Professor Carl Clarke

Department of Applied Health Sciences
Professor of Clinical Neurology
Honorary Consultant Neurologist

Contact details

Address
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Professor Clarke has a long history of research in Parkinson's disease and headache disorders. He runs large pragmatic clinical trials examining medical, surgical and rehabilitation interventions in Parkinson's disease (PD MED, PD SURG, PD REHAB, PD COMM and PD GEN).

Qualifications

  • FRCP
  • MD
  • MB ChB
  • BSc

Teaching

  • Instigator and co-ordinator of Birmingham Movement Disorders Course

Research

Professor Clarke has performed a wide variety of research work in Parkinson's disease over the last 30 years. This includes work on the MPTP primate model of the condition, examination of several potential diagnostic tests, systematic reviews of clinical trials in Parkinson's disease, and work on the effects of Parkinson's disease on quality of life and health economics. He led large pragmatic clinical trials examining medical, surgical and rehabilitation interventions in the condition (PD MED, PD SURG, PD REHAB and PD GEN). He was also the clinical advisor to the Technical Team preparing the NICE 2006 Parkinson's disease guidelines.

Other activities

  • Movement disorders clinics at City Hospital, Birmingham, Sandwell and West Birmingham Hospitals NHS Trust.
  • Director of Research and Development, Sandwell and West Birmingham Hospitals NHS Trust 2010-14.
  • Deputy Chair of NIHR Efficacy and Mechanisms Evaluation Board 2014-18.

Publications

Recent publications

Article

Sackley, CM, Rick, C, Brady, MC, Woolley, R, Burton, C, Patel, S, Masterson-Algar, P, Nicoll, A, Smith, CH, Jowett, S, Ives, N, Beaton, G, Dickson, S, Ottridge, R, Sharp, L, Nankervis, H, Clarke, CE & PD COMM Collaborative Group 2024, 'Lee Silverman voice treatment versus NHS speech and language therapy versus control for dysarthria in people with Parkinson’s disease (PD COMM): pragmatic, UK based, multicentre, three arm, parallel group, unblinded, randomised controlled trial', BMJ, vol. 386, e078341. https://doi.org/10.1136/bmj-2023-078341

Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease (Courage-PD) Consortium, Domenighetti, C, Sugier, P-E, Ashok Kumar Sreelatha, A, Schulte, C, Grover, S, Mohamed, O, Portugal, B, May, P, Bobbili, DR, Radivojkov-Blagojevic, M, Lichtner, P, Singleton, AB, Hernandez, DG, Edsall, C, Mellick, GD, Zimprich, A, Pirker, W, Rogaeva, E, Lang, AE, Koks, S, Taba, P, Lesage, S, Brice, A, Corvol, J-C, Chartier-Harlin, M-C, Mutez, E, Brockmann, K, Deutschländer, AB, Hadjigeorgiou, GM, Dardiotis, E, Stefanis, L, Simitsi, AM, Valente, EM, Petrucci, S, Duga, S, Straniero, L, Zecchinelli, A, Pezzoli, G, Brighina, L, Ferrarese, C, Annesi, G, Quattrone, A, Gagliardi, M, Matsuo, H, Kawamura, Y, Hattori, N, Nishioka, K, Chung, SJ, Kim, YJ & Clarke, CE 2022, 'Dairy intake and Parkinson's disease: a mendelian randomization study', Movement Disorders, vol. 37, no. 4, pp. 857-864. https://doi.org/10.1002/mds.28902

PD Med Collaborative Group 2021, 'Cost-effectiveness of dopamine agonists and monoamine oxidase B inhibitors in early Parkinson's disease', Movement Disorders, vol. 36, no. 9, pp. 2136-2143. https://doi.org/10.1002/mds.28623

Scobie , S, Jowett, S, Lambe, T, Patel, S, Woolley, R, Rowland, N, Rick, C, Smith, C, Brady , M, Clarke, CE & Sackley, C 2021, 'Lee Silverman voice treatment versus standard speech and language therapy versus control in Parkinson’s disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial', Pilot and Feasibility Studies, vol. 7, no. 1, 154. https://doi.org/10.1186/s40814-021-00888-y

Gray, R, Patel, S, Rowland, N, Rick, C, Woolley, R, Muzerengi, S, Gray, A, Jenkinson, C, McIntosh, E, Wheatley, K, Williams, A, Clarke, CE & PD Med Collaborative Group 2021, 'Long-term effectiveness of adjuvant treatment with catechol-O-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists among patients with Parkinson disease uncontrolled by Levodopa Therapy: the PD MED randomized clinical trial', JAMA Neurology. https://doi.org/10.1001/jamaneurol.2021.4736

Comprehensive Unbiaised Risk Factor Assessment for Genetics and Environment in Parkinson’s Disease (Courage-PD) consortium 2021, 'Mendelian randomisation study of smoking, alcohol, and coffee drinking in relation to Parkinson's disease', Journal of Parkinson's Disease. https://doi.org/10.3233/JPD-212851

Sackley, C, Rick, C, Au, P, Brady , MC, Beaton , G, Burton, C, Caulfield, M, Dickson , S, Dowling, F, Hughes, M, Rowland, N, Jowett, S, Masterson-Algar, P, Nicoll , A, Patel, S, Smith , CH, Woolley, R & Clarke, CE 2020, 'A multi-centre randomised controlled trial to compare the clinical and cost effectiveness of Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson’s disease: a study protocol for a randomised controlled trial', Trials, vol. 21, no. 1, 436. https://doi.org/10.1186/s13063-020-04354-7

Lang, AE, de Bie, RMA, Clarke, CE, Espay, AJ & Fox, SH 2020, 'Initiating pharmacotherapy in early Parkinson's disease', The Lancet Neurology, vol. 19, no. 8, pp. 643-644. https://doi.org/10.1016/S1474-4422(20)30225-8

Herd, C, Tomlinson, C, Rick, C, Scotton, W, Edwards, J, Ives, N, Clarke, CE & Sinclair, A 2019, 'Cochrane systematic review and meta-analysis of Botulinum toxin for the prevention of migraine', BMJ open, vol. 9, no. 7, e027953. https://doi.org/10.1136/bmjopen-2018-027953

Smith, CH, Patel, S, Woolley, RL, Brady, MC, Rick, CE, Halfpenny, R, Rontiris, A, Knox-Smith, L, Dowling, F, Clarke, CE, Au, P, Ives, N, Wheatley, K & Sackley, CM 2019, 'Rating the intelligibility of dysarthic speech amongst people with Parkinson's Disease: a comparison of trained and untrained listeners', Clinical Linguistics & Phonetics, vol. 33, no. 10-11, pp. 1063-1070. https://doi.org/10.1080/02699206.2019.1604806

American Genome Center 2019, 'The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight', Movement Disorders, vol. 34, no. 12, pp. 1851-1863. https://doi.org/10.1002/mds.27864

Herd, C, Cl, T, Rick, C, Scotton, WJ, Edwards, J, Ives, N, Clarke, CE & Sinclair, A 2018, 'Botulinum toxins for the prevention of migraine in adults', Cochrane Database of Systematic Reviews, no. 6, CD011616. https://doi.org/10.1002/14651858.CD011616.pub2

Review article

Carroll, C, Clarke, CE, Grosset, D, Rather, A, Mohamed, B, Parry, M, Reddy, P, Fackrell, R & Chaudhuri, KR 2024, 'Addressing Comorbidities in People with Parkinson’s Disease: Considerations From An Expert Panel', Journal of Parkinson's Disease, vol. 14, no. 1, pp. 53-63. https://doi.org/10.3233/jpd-230168

de Bie, RMA, Clarke, CE, Espay, AJ, Fox, SH & Lang, AE 2020, 'Initiation of pharmacological therapy in Parkinson's disease: when, why, and how', The Lancet Neurology, vol. 19, no. 5, pp. 452-461. https://doi.org/10.1016/S1474-4422(20)30036-3

Herd, CP, Tomlinson, CL, Rick, C, Scotton, WJ, Edwards, J, Ives, N, Clarke, CE & Sinclair, A 2018, 'Botulinum toxins for the prevention of migraine in adults', Cochrane Database of Systematic Reviews, vol. 6, CD011616. https://doi.org/10.1002/14651858.CD011616.pub2

View all publications in research portal

Expertise

Parkinson's Disease